Speech by the President of the Government at the signing ceremony of the agreement for the development and promotion of the National Center for Cardiovascular Research.

Spain José Luis Rodríguez Zapatero · Prime Minister of Spain

14 December 2005 · Signing ceremony of the agreement for the development and promotion of the National Center for Cardiovascular Research

Context
Zapatero spoke at the signing ceremony establishing a public-private foundation to fund and develop Spain's National Center for Cardiovascular Research in December 2005.
Main themes
Cardiovascular research, Carlos III National Center for Cardiovascular Research, biomedical research in Spain, public-private partnership, National Health System, scientific excellence, Valentín Fuster, research funding, transplants and regenerative medicine, social responsibility of companies
Duration
~14 min
50th percentile
Words
1,715
50th percentile
Sentences
50
33rd percentile
Readability
26
11th percentile
Grade
17.6
92nd percentile
Syntax
3.45
92nd percentile
Vocabulary
2.17
42nd percentile

Translated from Spanish

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 46%46%
  • Economic 40%40%
  • Ceremonial 10%10%
  • Institutional 4%4%
  • Geopolitical 0%0%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 0%

50 sentences in 33 paragraphs

Dear friends, dear Valentín, dear Minister,

The truth is that this event brings me special satisfaction, the signing of this agreement which is a joint effort between companies and the Government, in which above all there is passion, intelligence, and generosity from a recognized and admired scientist, Valentín Fuster.

This agreement will serve to ensure that the Carlos III National Center for Cardiovascular Research, which is already carrying out significant work, becomes a leading institution in a field of special importance for the health of citizens: the field of cardiovascular research.

In the array of scientific disciplines that make up the landscape of research, biomedical research has always yielded excellent results in Spain. It is worth recalling Santiago Ramón y Cajal and Severo Ochoa, of whom we celebrate the centenary of his birth this year, and it is good that in memory and tribute this country makes significant advances in what biomedical research represents.

But Spanish science -- we must say it with satisfaction -- has long made the leap from isolated individual efforts to organized teamwork. That is why we already have several generations of scientists who, through excellent work recognized internationally, demonstrate the solid landscape that biomedical research presents in our country.

It is evident that the research activity yields undeniable and valuable benefits for society. This paradigm is even more pronounced in the case of biomedicine. Every advance and every discovery in this field has a direct application in improving the living conditions of our citizens. In a social state like ours, the basic research/clinical application binomial must be enhanced so that the knowledge obtained in laboratories equipped with the most advanced technologies constitutes, along with healthcare practice, the day-to-day exercise of medicine in our valued and beloved National Health System.

Thus, clinical research, as a complement and source of rigor for the healthcare professionals' assistance activity, is one of the best contributions that Health Systems can make to patients and society in general.

In Spain, we have a National Health System that is valued by citizens as the most satisfactory public service. Within it, levels of excellence are achieved in the most diverse medical disciplines, allowing our country to enjoy evident international recognition and our citizens, one of the highest life expectancies in the world.

In this regard, I want to highlight the continuous work of the University; of hospitals, among which we must emphasize university hospitals with their special role as crystallizing centers of health research; of public research organizations and also of private centers in the industrial sector; in particular, pharmaceutical industries that, by combining efforts and identifying priorities, have achieved undeniable advances that benefit the well-being of all society.

The Carlos III National Center for Cardiovascular Research, whose advisory committee is led by the invaluable experience of Dr. Fuster, and the Foundation we are forming today will involve in its funding not only the Administration and companies in the health sector but also companies from other sectors that consider that investment in research, and specifically in health research, constitutes one of the best ways to participate in achieving a more just and more supportive society with a higher quality of life.

With this, once again, our companies, our best companies, demonstrate their commitment and high level of social responsibility. These are companies that today conquer markets around the world, but that today also win the hearts of Spaniards with the contribution they are making to the future of health and the improvement of life for our citizens.

I want to emphasize that this Foundation becomes, with this act and this commitment, a world reference center and that the funding until 2012 will be 260 million euros, of which the private sector will contribute 35 percent.

But today is also a good day to refer to some other examples of what our strength in the field of biomedical research represents. I want to recall the work carried out by Spanish doctors in the field of transplants -- I want to have a special memory for Dr. Margarit, a pioneer of liver transplants in Spain and recently deceased -- who have made the Spanish National Transplant Organization a model to follow in the countries around us.

Let the research in regenerative medicine serve as an example, which has several groups working in Spanish hospitals and is reaching levels comparable to those carried out in the most advanced countries. Let ophthalmology or psychiatry serve as examples, areas in which our doctors enjoy significant prestige and in which several of them are world leaders. Finally, let cardiology serve as an example, in which Dr. Valentín Fuster occupies a prominent place.

Biomedical research is, on the other hand, an excellent example of how the coordinated activity of all involved parties can lead to the best possible results. Therefore, my satisfaction is doubled when presiding over the signing of this agreement for the development and promotion of the Carlos III National Center for Cardiovascular Research, and it is because this is an important step forward in my Government's policy on research.

Spain today leads economic growth in the European Union, leads employment growth in the European Union, leads the good health of public accounts, leads with large companies in conquering major international markets, and we have committed to being leaders in the field of research in just a few years to ensure the future that Spaniards deserve and can aspire to.

As a Government, we have made a very determined bet on knowledge, innovation, and development as a substantial basis for achieving the objectives of the Lisbon Strategy; a Strategy that aims to place Europe and Spain at a level of competitiveness comparable to or superior to that of the most advanced global environments.

My wish is for all of Europe to achieve the Lisbon objectives, but beyond what the European Union as a whole does, my commitment and the decision of Spanish society, which is even more important, is that Spain does meet the objectives of the Lisbon Strategy and positions itself as a competitive society, essentially through knowledge, innovation, and research.

When we came to power, we identified three shortcomings we faced in terms of R&D&I: the limited public/private collaboration in research, the insufficient critical mass in the science and technology system, and the significant delay in the Information Society. To overcome these shortcomings, as you know, the Government has approved an ambitious program, the "Ingenio 2010 Program," whose objectives I want to recall here today: to double the R&D investment ratio, going from 1 percent of GDP in 2003 to 2 percent in 2010; to increase the contribution of the private sector, reaching 55 percent in 2010 in our entire research system, and to reach the EU average in the percentage of GDP allocated to Information and Communication Technologies, reaching 7 percent in 2010.

The effort to achieve these objectives is supported by four pillars that I want to briefly recall.

The first of these consists of providing more resources to R&D&I. As you know, in 2005 the civil R&D&I budget increased by 27 percent and in 2006 it will increase by 30.9 percent, with both credits and grants growing. The 2006 budget represents the highest growth in the last fifteen years, a growth that we can qualify as historic and that exceeds the Government's commitment to increase R&D&I budget allocations by 25 percent annually throughout the Legislature.

The second pillar consists of strengthening resources in new actions that respond to the main challenges of the Spanish science and technology system, which are found in three main lines:

- The Cenit Program, which consists of strategic technical research consortia to stimulate public/private collaboration, which is divided into the following actions:

The second line is the Consolider Program, which aims to increase critical mass and research excellence. To this end, we have designed four actions:

The "Plan Avanza" is the line to ensure our progress in the Information Society and to converge as quickly as possible with Europe in companies, in Administrations, and, very specifically, in the field of Education.

In addition, as you know, we want to carry out regulatory reforms to promote Research, Development, and Innovation, and to help reduce bureaucratic obstacles within the Administration with the Agency Law, with the new Regulation of the General Subsidies Law, and with the Public Sector Contracts Law.

The last pillar is encompassed in the so-called Comprehensive Monitoring and Evaluation System, which will allow for continuous review and adjustment of R&D policies.

I want to conclude by reaffirming the Government's interest, which expresses the interest of society, in changing the trend and composition of the factors responsible for the development and economic progress of Spain.

The agreement we sign today has a historic character and reflects one of the best moments in our country, where companies, increasingly powerful companies, commit themselves even more socially and where the country -- public sector and private sector -- sets the goal of being a leader in biomedical research in the field of cardiology. This undoubtedly connects with the best ambitions of this modern Spain, increasingly efficient and increasingly rooted in those values that bring progress, stability, and future: culture, knowledge, health, and good coexistence.

Today, moreover, is a day when this country decides to take special care of the heart, because the signing of this agreement coincides with the approval, which will take place in the Congress of Deputies, that with tenacity, rigor, and ambition in the interest of the health of Spaniards will take place this morning of a law to drastically curb tobacco consumption.

We commit the Administration, or in other words, citizens, and companies to take better care of the hearts of our citizens, to promote research, and to broaden health expectations. All of this undoubtedly represents greater well-being and, therefore, more expectation of culture and citizen empowerment.

These policies, for a more modern, healthier, and more productive Spain, are the policies that Spanish society of the 21st century wants; that society which, so effectively and committedly, is served by the companies that sit here today and sign this commitment, of which, as I have already said on other occasions, I am very proud as President of the Government of Spain and I want all Spaniards to know this.

Thank you very much.